For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Noriaki Ishida, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com
Daiichi Sankyo Espha to Launch New Generic Products
Tokyo, Japan (December 14, 2012) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that its Japanese established pharmaceuticals subsidiary, Daiichi Sankyo Espha Company, Limited (hereafter, Daiichi Sankyo Espha), will launch five generic products with two active ingredients.
Overview
1. Product names/therapeutic categories
|
Product name
|
Therapeutic category
|
Original Brand Name
|
|
Quetiapine tablets 25 mg DSEP
|
Antipsychotic
|
Seroquel®
|
|
Quetiapine tablets 100 mg DSEP
|
|
Quetiapine tablets 200 mg DSEP
|
|
Mosapride Citrate tablets 2.5 mg DSEP
|
Gastroprokinetic agent
|
Gasmotin®
|
|
Mosapride Citrate tablets 5 mg DSEP
|
2. Product attributes
Daiichi Sankyo Espha has created innovative labeling on tablets and PTP sheets to make them easier for patients to see and understand.
PTP sheet design concept
* “Pitch control” - Through pitch control on both sides of the tablet, it is possible to display the product name and dosage on each pill, making it easier for patients to recognize.
* Design that allows for easy identification - Color and special markings make the tablets easier to identify.
* GS1 data barcode - In order to prevent medication errors, the GS1 data barcode is marked on each tablet.
Tablet ideas
* Tablet color and shape - Similar to standard products, the tablet color of Quetiapine and the tablet shape of Mosapride differ for each dosage to make them clearly distinguishable.
* Tablet printing (Quetiapine only) - The product name and dosage of each pill are laser printed on each side of Quetiapine tablets using a universal font (utilizing some Chinese characters) so that patients can clearly distinguish them.
Example: PTP sheets and Quetiapine 100 mg DSEP tablets
Example: PTP sheets and Mosapride Citrate 5 mg DSEP tablets
About Daiichi Sankyo Espha
Daiichi Sankyo Espha was created in April 2010 to manufacture and market generic drugs and Daiichi Sankyo established pharmaceuticals(*1) to accommodate rising demand based on the spirit of the Daiichi Sankyo Group’s corporate philosophy(*2) of supplying pharmaceuticals to address diverse medical needs.
Daiichi Sankyo Espha strives to provide pharmaceuticals that provide peace of mind for users by fulfilling the most important pharmaceutical criteria of quality, information, and stable supply while delivering the economic benefits of generics.
Company overview
Company name: Daiichi Sankyo Espha Co., Ltd.
Established: April 1, 2010
Business: Manufacture and sale of pharmaceuticals
Capital: 450 million yen
Representative: President Hiroto Yoshiwaka
Headquarters: 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo
(*1) Established pharmaceuticals
This is a general term for pharmaceuticals that are long-running contributors to healthcare and demonstrate efficacy, safety and are established in use. Daiichi Sankyo Espha handles some generics and some long-listed Daiichi Sankyo pharmaceuticals.
(*2) Daiichi Sankyo Group corporate philosophy
To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs
End